Reported Earlier, Tandem Diabetes Care, Inc. Receives FDA Clearance For The Tandem Mobi Insulin Pump For People With Diabetes Age 6 And Up, Expanding The Company's Portfolio Of Products
Portfolio Pulse from Happy Mohamed
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has received FDA clearance for the Tandem Mobi insulin pump for people with diabetes age 6 and up. The Tandem Mobi is fully controllable from a mobile app and is the world's smallest durable automated insulin delivery system. A limited release of Tandem Mobi is expected to start in late 2023 with full commercial availability planned in early 2024.
July 11, 2023 | 4:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tandem Diabetes Care's new FDA-approved insulin pump could potentially increase the company's market share and revenues. However, the product will not be fully available until early 2024.
The FDA clearance of Tandem's new insulin pump expands the company's product portfolio, potentially attracting more customers and increasing revenues. However, the full impact will not be felt until the product is fully available in 2024.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100